5 Analysts Assess Molina Healthcare: What You Need To Know
Portfolio Pulse from Benzinga Insights
Five analysts have recently updated their ratings on Molina Healthcare (NYSE:MOH), showing a mix of opinions. The average 12-month price target for MOH has been raised to $420.6, indicating a 10.25% increase from the previous target. Analysts from Barclays, Truist Securities, Wells Fargo, Cantor Fitzgerald, and UBS have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. Molina Healthcare's financials show strong revenue growth, net margin, ROE, and ROA, but a high debt-to-equity ratio poses a challenge.
March 06, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Molina Healthcare's average 12-month price target has been raised to $420.6, reflecting a positive outlook from analysts. The company's strong financial performance, including revenue growth and profitability, supports this view, though its high debt-to-equity ratio is a concern.
The increase in the average 12-month price target for MOH by analysts indicates a bullish outlook, supported by the company's recent financial performance. The positive revenue growth, net margin, ROE, and ROA suggest that MOH is managing its operations efficiently and profitably. However, the high debt-to-equity ratio is a potential risk factor that investors should monitor. The mixed opinions among analysts, with adjustments in ratings and price targets, reflect ongoing assessments of the company's market position and potential.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100